5 results about "Antisense DNA" patented technology

To provide compositions and methods for the treatment of leukodystrophy.SOLUTION: Provided is use of administering an effective amount of a compound that down-modulates the expression of both wild-type and mutant TUBB4-A in the manufacture of a pharmaceutical composition for the treatment or prevention of hypomyelination and atrophy of the basal ganglia (H-ABC) leukodystrophy, the pharmaceutical composition ameliorating symptoms of H-ABC, and the compound being selected from short hairpin RNA (shRNA), short interfering RNA (siRNA), antisense RNA, antisense DNA, chimeric antisense DNA / RNA, microRNA, and a ribozyme that is sufficiently complementary to either the gene or mRNA encoding TUBB4A.SELECTED DRAWING: Figure 1-1

Interfering nucleic acids and methods of their use in treat prostate cancers, such as aggressive prostate cancers. The nucleic acids may be, for example, short interfering RNA (siRNA), short hairpin RNA (shRNA), antisense RNA, DNA, antisense DNA, Chimeric Antisense DNA / RNA, and microRNA (miRNA) oligonucleotides. The oligonucleotide has a seed sequence that is complementary to a sequence of either a gene or an mRNA encoding an androgen receptor (AR) coregulator or a fragment having AR coregulator activity. The nucleic acid compound may have a non-natural modification in the oligonucleotide, and / or an organic moiety conjugated to the oligonucleotide. The oligonucleotide has inhibitory activity against the expression or biological activity of the AR coregulator.

The present invention discloses a DNA hydrogel with cascade reaction function, its preparation method and application. The carrier is a pure DNA system, which is formed by means of rolling circle replication. During the rolling circle replication process, an AS1411 nucleic acid aptamer sequence with targeting function and an antisense DNA sequence of hypoxia-inducible factor HIF-1α are generated. A nucleic acid aptamer capable of targeting tumor cells is designed on the linear template, and cholesterol is designed on the nucleic acid aptamer sequence. After high-speed centrifugation and standing, self-assembly forms a DNA hydrogel. This DNA hydrogel has been successfully applied to the drug sustained-release system, has good biocompatibility, and simultaneously loads chlorin e6 (Ce6), heme and glucose oxidase (GOx), showing broad prospects in the fields of inhibiting the growth of malignant tumor cells and biomedicine, etc.

The present application relates to a kind of loaded vesicle and its preparation method, kit, medicine and purposes.Loaded vesicle includes DNA modified nanoparticle, vesicle layer, the vesicle layer is coated in the outside of the DNA modified nanoparticle, antisense DNA, the antisense DNA is loaded on the nanoparticle and / or the vesicle layer;Preparation method includes: DNA modified nanoparticle and vesicle layer are assembled, obtain frame, antisense DNA is mixed with the frame and is reacted, so that the antisense DNA is loaded on the DNA modified nanoparticle or the vesicle layer, and loaded vesicle is prepared.After the loaded vesicle enters cell, it can release antisense DNA, it can target after mRNA complementary combination, inhibit mRNA translation, so as to promote cancer cell apoptosis, with the advantages such as strong stability and controllable release antisense DNA;And, the preparation method is simple to operate.

The invention relates to newly identified nucleic acids, ribonucleic acids (RNAs) and deoxyribonucleic acids (DNAs), specifically esiRNAs / ERNAs (effective small interfering RNAs) and RNAs derived therefrom, as well as eASO (effective antisense DNA oligonucleotides), collectively referred to as eNAs (effective nucleic acids), which can be used in RNA silencing / RNAi or RNA silencinglantisense methods, as active agents against various variable plant pathogens. To identify the eNAs, an “eNA screen” was applied for the first time in standardized form to target RNAs of various plant pathogens. As a result, a new class of active agents against pathogens was identified and successfully used. The invention further relates to the construction of double-stranded ribonucleic acids, edsRNAs (effectively double-stranded RNAs), which contain nucleotide sequences of identified esiRNAs / ERNAs or related RNAs derived therefrom, and which can be successfully used in the RNA silencing / RNAi methods as active agents in plant protection against variable plant pathogens.